article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

The post Scleroderma drug trial shows up to 60% improvement appeared first on Drug Discovery World (DDW). It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

article thumbnail

Abcuro raises $155m for KLRG1 drug trial

pharmaphorum

Abcuro raises $155m for KLRG1 drug trial Phil.Taylor Thu, 17/08/2023 - 14:54 Bookmark this

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA sets out its thinking on psychedelic drug trials

pharmaphorum

FDA sets out its thinking on psychedelic drug trials Phil.Taylor Mon, 26/06/2023 - 07:15 Bookmark this

article thumbnail

Psychedelic depression drug trial shows rapid and robust response

Drug Discovery World

The post Psychedelic depression drug trial shows rapid and robust response appeared first on Drug Discovery World (DDW).

article thumbnail

Patients achieve 19% weight loss in obesity drug trial

Drug Discovery World

The post Patients achieve 19% weight loss in obesity drug trial appeared first on Drug Discovery World (DDW). After 46 weeks of treatment, up to 40% of people who reached the highest two doses of survodutide achieved a weight loss of at least 20%, versus 0% with placebo (actual treatment analysis).

article thumbnail

Alnylam details anticipated results from heart disease drug trial

Bio Pharma Dive

Fuller data from Alnylam’s APOLLO-B trial confirm the success reported by the company last month, but won’t end a debate on the degree of benefit offered by its drug.

article thumbnail

Phase III pulmonary fibrosis drug trial fails

Drug Discovery World

“The REBUILD study did not match the outcomes we saw in the exploratory Phase II study in this patient population; however, the overall outcome of this pivotal validation study is conclusive and we do not see a path forward for continuing the REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer.